BACKGROUND: It is unknown whether sex and race influence clinical outcomes following primary human immunodeficiency virus type 1 (HIV-1) infection. METHODS: Data were evaluated from an observational, multicenter, primarily North American cohort of HIV-1 seroconverters. RESULTS: Of 2277 seroconverters, 5.4% were women. At enrollment, women averaged .40 log₁₀ fewer copies/mL of HIV-1 RNA (P < .001) and 66 more CD4(+) T cells/μL (P = .006) than men, controlling for age and race. Antiretroviral therapy (ART) was less likely to be initiated at any time point by nonwhite women and men compared to white men (P < .005), and by individuals from the southern United States compared to others (P = .047). Sex and race did not affect responses to ART after 6 months (P > .73). Women were 2.17-fold more likely than men to experience >1 HIV/AIDS-related event (P < .001). Nonwhite women were most likely to experience an HIV/AIDS-related event compared to all others (P = .035), after adjusting for intravenous drug use and ART. Eight years after diagnosis, >1 HIV/AIDS-related event had occurred in 78% of nonwhites and 37% of whites from the southern United States, and 24% of whites and 17% of nonwhites from other regions (P < .001). CONCLUSIONS: Despite more favorable clinical parameters initially, female HIV-1-seroconverters had worse outcomes than did male seroconverters. Elevated morbidity was associated with being nonwhite and residing in the southern United States.
BACKGROUND: It is unknown whether sex and race influence clinical outcomes following primary human immunodeficiency virus type 1 (HIV-1) infection. METHODS: Data were evaluated from an observational, multicenter, primarily North American cohort of HIV-1 seroconverters. RESULTS: Of 2277 seroconverters, 5.4% were women. At enrollment, women averaged .40 log₁₀ fewer copies/mL of HIV-1 RNA (P < .001) and 66 more CD4(+) T cells/μL (P = .006) than men, controlling for age and race. Antiretroviral therapy (ART) was less likely to be initiated at any time point by nonwhite women and men compared to white men (P < .005), and by individuals from the southern United States compared to others (P = .047). Sex and race did not affect responses to ART after 6 months (P > .73). Women were 2.17-fold more likely than men to experience >1 HIV/AIDS-related event (P < .001). Nonwhite women were most likely to experience an HIV/AIDS-related event compared to all others (P = .035), after adjusting for intravenous drug use and ART. Eight years after diagnosis, >1 HIV/AIDS-related event had occurred in 78% of nonwhites and 37% of whites from the southern United States, and 24% of whites and 17% of nonwhites from other regions (P < .001). CONCLUSIONS: Despite more favorable clinical parameters initially, female HIV-1-seroconverters had worse outcomes than did male seroconverters. Elevated morbidity was associated with being nonwhite and residing in the southern United States.
Authors: John A Fleishman; Kelly A Gebo; Erin D Reilly; Richard Conviser; W Christopher Mathews; P Todd Korthuis; James Hellinger; Richard Rutstein; Philip Keiser; Haya Rubin; Richard D Moore Journal: Med Care Date: 2005-09 Impact factor: 2.983
Authors: Nancy F Crum; Robert H Riffenburgh; Scott Wegner; Brian K Agan; Sybil A Tasker; Katherine M Spooner; Adam W Armstrong; Susan Fraser; Mark R Wallace Journal: J Acquir Immune Defic Syndr Date: 2006-02-01 Impact factor: 3.731
Authors: Johan P Mackenbach; Irina Stirbu; Albert-Jan R Roskam; Maartje M Schaap; Gwenn Menvielle; Mall Leinsalu; Anton E Kunst Journal: N Engl J Med Date: 2008-06-05 Impact factor: 91.245
Authors: Kelly A Gebo; John A Fleishman; Richard Conviser; Erin D Reilly; P Todd Korthuis; Richard D Moore; James Hellinger; Philip Keiser; Haya R Rubin; Lawrence Crane; Fred J Hellinger; W Christopher Mathews Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: Fiona M Ewings; Krishnan Bhaskaran; Ken McLean; David Hawkins; Martin Fisher; Sarah Fidler; Richard Gilson; Demelza Nock; Ray Brettle; Margaret Johnson; Andrew Phillips; Kholoud Porter Journal: AIDS Date: 2008-01-02 Impact factor: 4.177
Authors: Christopher J L Murray; Sandeep C Kulkarni; Catherine Michaud; Niels Tomijima; Maria T Bulzacchelli; Terrell J Iandiorio; Majid Ezzati Journal: PLoS Med Date: 2006-09 Impact factor: 11.069
Authors: Linda Beer; Heather Bradley; Christine L Mattson; Christopher H Johnson; Brooke Hoots; Roy L Shouse Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Rupak Shivakoti; Erin R Ewald; Nikhil Gupte; Wei-Teng Yang; Cecilia Kanyama; Sandra W Cardoso; Breno Santos; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Javier R Lama; Umesh Lalloo; Fatima Zulu; Jyoti S Pawar; Cynthia Riviere; Nagalingeswaran Kumarasamy; James Hakim; Richard Pollard; Barbara Detrick; Ashwin Balagopal; David M Asmuth; Richard D Semba; Thomas B Campbell; Jonathan Golub; Amita Gupta Journal: Clin Nutr Date: 2018-05-29 Impact factor: 7.324
Authors: Amie L Meditz; Joy M Folkvord; Ngan H Lyle; Kristina Searls; Yolanda S Lie; Eoin P Coakley; Martin McCarter; Samantha Mawhinney; Elizabeth Connick Journal: J Infect Dis Date: 2013-10-31 Impact factor: 5.226
Authors: Catherine R Lesko; Stephen R Cole; William C Miller; Daniel Westreich; Joseph J Eron; Adaora A Adimora; Richard D Moore; W Christopher Mathews; Jeffrey N Martin; Daniel R Drozd; Mari M Kitahata; Jessie K Edwards; Michael J Mugavero Journal: Clin Infect Dis Date: 2015-03-12 Impact factor: 9.079
Authors: Baba M Musa; Musa A Garbati; Ibrahim M Nashabaru; Shehu M Yusuf; Aisha M Nalado; Daiyabu A Ibrahim; Melynda N Simmons; Muktar H Aliyu Journal: Int Health Date: 2016-12-09 Impact factor: 2.473
Authors: Sheri D Weiser; Abigail Hatcher; Edward A Frongillo; David Guzman; Elise D Riley; David R Bangsberg; Margot B Kushel Journal: J Gen Intern Med Date: 2012-08-18 Impact factor: 5.128